Immunocore Holdings PLC (NAS:IMCR)
$ 46.05 -1.93 (-4.02%) Market Cap: 2.30 Bil Enterprise Value: 1.85 Bil PE Ratio: 0 PB Ratio: 5.07 GF Score: 73/100

Immunocore Holdings PLC at Needham Healthcare Conference (Virtual) Transcript

Apr 14, 2022 / 01:30PM GMT
Release Date Price: $35.05 (-3.63%)
Gil Blum
Needham & Company, LLC - Analyst

Good morning and welcome to day four of the Needham & Company healthcare conference. My name is Gil Blum and I am a senior biotech analyst here at Needham & Company, covering the immuno-oncology and gene therapy subsectors. It is my pleasure to have with me today Immunocore's management team. (Conference Instructions) And with that, you have the stage.

Bahija Jallal
Immunocore Holdings plc - CEO

Good morning and thank you for having us to talk about Immunocore today, it's our distinct pleasure to do so. Our mission is to harness -- this is our forward-looking statements. Our mission is to harness the power of the immune system to fight diseases with targeted, off-the-shelf, bispecific, soluble T cell receptor. And we believe that this platform can address unmet medical need in immuno-oncology and beyond.

And as a matter of fact, the last -- in January, we had the distinct pleasure of actually validating this platform with the approval of KIMMTRAK. That's the first and only FDA-approved therapy

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot